DR. STEPHEN GATELY obtained his Ph.D. from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital. Thereafter he joined the Department of Medicine, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine as Research Assistant Professor where his research focused on the identification and development of pharmacologic and endogenous inhibitors of angiogenesis. During this time, Dr. Gately served as a consultant to the Oncology Clinical Research Team at Searle/Monsanto (now Pfizer). In this position he was responsible for scientific and technical input on clinical trial designs to rapidly assess the utility of antiangiogenic compounds. Additional responsibilities included interacting with discovery scientists to understand drug mechanism of action to aid in the identification of potential biomarkers for early clinical proof of drug activity studies. He then joined the oncology-focused biopharmaceutical company NeoPharm where he served as Executive Director of Translational Medicine. In this position Dr. Gately had responsibility for the design and implementation of basic and clinical research studies to enhance the scientific understanding and positioning of existing products and development candidates. Dr. Gately then served as a consultant to Takeda Pharmaceuticals North America, Medical and Scientific Affairs group where he was responsible for the scientific integration of non-clinical, clinical and regulatory data on portfolio compounds for optimal commercial planning. In addition he was involved in the scientific due diligence for oncology new business development opportunities. Dr. Gately is currently President and Chief Executive Officer at Translational Drug Development (TD2), and adjunct Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine.
DR. DANIEL VON HOFF is TD2’s Chief Development Officer. He also serves as Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona, as well as Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.
Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 569 papers, 135 book chapters and over 1000 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.
Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world's largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and former Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
TARA FRANKS' role at TD2 involves the oversight of business development, marketing, administrative, operational, and financial activities. She is also responsible for managing strategic business initiatives and collaborations. Ms. Franks has a strong fifteen year track record of success in business development and operations for preclinical, regulatory, and clinical services in the oncology space as well as project management of oncology programs in early stage development. Ms. Franks has spent the last eight years heading up operations at TD2. During her time at the company she has helped to significantly grow top line revenue, streamline operations, coordinate the build-out of both preclinical and clinical service lines, and grow the client base.
Ms. Franks holds a Master of Business Adminstration from Arizona State University and graduated magna cum laude from the University of Arizona, where she holds a Bachelor of Science in Business Administration and a Bachelor of Arts in Ecology and Evolutionary Biology.
ERIC TOOKER is Vice President and General Counsel for Translational Drug Development, LLC, a specialty CRO and drug development company.
He is also a Manager of Translational Accelerator, LLC, a $20 million biotech venture fund in Phoenix, Arizona.
Mr. Tooker previously served as President and Chief Executive Officer of MCS Biotech Resources, which provides business, legal, administrative, and support services to expert medical consultants and start up companies. Mr. Tooker also previously served as Vice President and General Counsel for Central Newspapers, Inc.
Mr. Tooker has extensive experience in advising executive business teams throughout his 25 years as in-house counsel. In that role with Conseco, Inc., he served as legal counsel and business adviser for a significant private equity portfolio and led mergers and acquisitions and associated bank financings.
Mr. Tooker earned a B.S. degree in education from Miami University-Ohio and a J.D. from the University of Michigan Law School.
PAUL GONZALES has twenty years of experience working in oncology drug development. Paul has been with TD2 for over 10 years working with biotech clients and maturing the nonclinical research department. Mr. Gonzales' vast experience in preclinical oncology models contributes to the design and execution of client's preclinical development plans. Mr. Gonzales has aided in the advancement of many of today's oncology treatments at their early development phase. Mr. Gonzales trained in the oncology drug development field at the Cancer Therapy and Research Center.
Mr. Gonzales received his Bachelor’s degree in Biomedical Sciences from Texas A&M University-College Station.
JENNIFER KEPPLER has over 20 years of experience in translational research, clinical trials and regulatory strategy across academic, industry and CRO settings. Prior to joining TD2 as Vice President of Translational Medicine, she was the Chief Operating Officer and acting VP of Clinical Development for ImaginAb where she oversaw the pre-clinical translation, as well as clinical and regulatory strategy for biologic-based drug products. Over the course of her career, she has overseen IND filings from Phase I through Phase II for both small and large molecules.
Ms. Keppler has a Master of Business Administration from the University of Southern California. She also holds a Bachelor of Science in Marketing from the University of Phoenix and an Associate’s of Science in Nuclear Medicine Technology. Ms. Keppler is also author of numerous scientific papers on clinical PET/radiopharmaceuticals and diagnostic imaging.
MATTHEW WITMAN has more than fifteen years’ experience in business development and contract management/negotiation within the life sciences and commercial litigation industries. Mr. Witman's role at TD2 involves the oversight of preclinical and clinical proposals and contracts group, in addition to drafting, negotiating and managing internal and external contracts for TD2.
Mr. Witman graduated with a Bachelor of Arts from Trinity College (CT) and has previously held paralegal and legal document preparer certifications
SUSAN TESSMANN serves as Vice President of Clinical Operations at TD2. Ms. Tessmann is responsible for overseeing and managing the TD2 clinical team including project management, data management, medival monitoring, clinical monitoring, and administrative functions. She has over 27 years of experience working in the CRO field, including eight years in Clinical Pharmacology running Phase I and Phase II clinical trials, eight years in Human Resources and eleven years in Preclinical Toxicology.
Ms. Tessmann holds a Masters of Business Administration from the University of Phoenix as well as a Bachelor of Science in Business management and Associates of Applied Science in Veterinary Technology. She is a certified Project Managment Professional, training facilitator, and a Six Sigma Greenbelt.